An open label, phase II study suggests 600 mg IV every 4 weeks has a similar benefit-risk profile compared to 350 mg IV every 3 weeks (Rischin D, Hughes BGM, Basset-SÃcguin N, et al. High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. Journal for ImmunoTherapy of Cancer 2024;12:e008325. doi: 10.1136/jitc-2023-008325). This dosing is not approved in Canada or the US.
Metastatic / locally advanced cutaneous squamous cell carcinoma OR basal cell carcinoma - 2 years total treatment (35 doses at every 3 weeks) or until PD / unacceptable toxicity.
Chemotherapy (1L Advanced or Metastatic NSCLC) - 108 weeks (36 doses at every 3 weeks) or until PD / unacceptable toxicity.
Other Indications - Until PD / unacceptable toxicity.